Renal cell carcinoma (RCC), also called renal cell cancer or renal cell adenocarcinoma, which comprises almost all type of kidney cancers. RCC usually begins as a tumor growing in one of the kidneys, which can easily develop in both the kidneys, at times it can also be advanced or metastatic that can easily spread to the other parts of the body. The tumor can invade a large vein leading out of the kidney. It can also spread to the lymph system and other organs (lungs being the most vulnerable).
The renal cell carcinoma on the basis of the location and cellular lining and the pathway followed by the tumor for the growth is historically divided into various sub types such as Clear cell RCC, Papillary RCC, Chromophobe RCC, Collecting duct RCC and Unclassified RCC. When RCC is in its early stages, patients may be symptom free but as the disease progresses, symptoms may include a lump in the abdomen, blood in the urine, unexplained weight loss, loss of appetite, fatigue, vision problems, excessive hair growth (in women), etc. The risk factors associated with advanced RCC include excess body weight, hypertension, cigarette smoking, genetic factors, etc.
Get FREE sample copy at:
https://www.delveinsight.com/sample-request/advanced-renal-cell-carcinoma-rcc-market
The Advanced Renal Cell Carcinoma market report also covers emerging drugs, current treatment practices, Advanced Renal Cell Carcinoma market share of the individual therapies, current and forecasted Advanced Renal Cell Carcinoma Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Advanced Renal Cell Carcinoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Advanced Renal Cell Carcinoma Market Key Facts
The total incident population of Advanced Renal Cell Carcinoma (RCC) in the 7MM markets was found to be 69,429 cases in 2017.
The total diagnosed incident population of RCC in the United States was found to be 53,405 cases in 2017.
As per Delveinsight estimates, In EU5 countries, France had the maximum diagnosed incident population of RCC i.e., 5,485 cases followed by Germany with 4,719 cases in 2017. While the lowest number of cases were found in Spain with 2,543 cases in 2017.
In Japan, the total cases of advanced/metastatic RCC were found to be 7,628 cases in 2017, which will increase in the forecast period 2020–2030.
Key Benefits of Advanced Renal Cell Carcinoma Market Report
-
Advanced Renal Cell Carcinoma market report provides an in-depth analysis of Advanced Renal Cell Carcinoma Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
-
The Advanced Renal Cell Carcinoma market report will help in developing business strategies by understanding the Advanced Renal Cell Carcinoma Market trends & developments, key players and future market competition that will shape and drive the Advanced Renal Cell Carcinoma market in the upcoming years.
-
The Advanced Renal Cell Carcinoma market report covers Advanced Renal Cell Carcinoma current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
-
The report provides a detailed assessment of the Advanced Renal Cell Carcinoma market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Advanced Renal Cell Carcinoma Market
The treatment paradigm of advanced renal cell carcinoma (RCC) has undergone a dramatic evolution over the last decade. The improvements in treatment is due to better understanding of the biologic factors driving cancer growth. The clarification of the importance of the VEGF and mTOR pathways led to the introduction of several novel agents in the treatment of advanced or metastatic renal cell carcinoma (mRCC). Currently there are a number of treatment options available to treat the patients with advanced RCC. The treatment ranges from excising out the tumor to using pharmacological interventions.
Increasing awareness, introduction of novel drugs and changing lifestyle are some of the key factors driving the growth of Advanced Renal Cell Carcinoma market globally
The Advanced Renal Cell Carcinoma market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Advanced Renal Cell Carcinoma market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Advanced Renal Cell Carcinoma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Advanced Renal Cell Carcinoma Epidemiology
The Advanced Renal Cell Carcinoma epidemiology section covers insights about historical and current Advanced Renal Cell Carcinoma patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Advanced Renal Cell Carcinoma Drugs Uptake and Key Market Players
The Advanced Renal Cell Carcinoma Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Advanced Renal Cell Carcinoma market or expected to get launched in the market during the study period. The analysis covers Advanced Renal Cell Carcinoma market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Some of the key players in the Advanced Renal Cell Carcinoma market includes:
Merck
Eisai
Pfizer
Novartis
Exelixis
Genentech
AstraZeneca
Pharmacyclics
AVEO Oncology
X4 Pharmaceuticals
Bristol-Myers Squibb
Nektar Therapeutics
Calithera Biosciences
And few others.
Drugs Covered
SRF388
Nintedanib
Crizotinib
Ibrutinib/Nivolumab
Telaglenastat (CB-839)
Savolitinib (AZD-6094)
Mavorixafor (X4P-001)
Pembrolizumab (MK-3475)/Bevacizumab
Bempegaldesleukin (NKTR-214) and NKTR-262
And many others.
Table of Content
1. Key Insights
2. Executive Summary
3. Advanced Renal Cell Carcinoma Competitive Intelligence Analysis
4. Advanced Renal Cell Carcinoma Market Overview at a Glance
5. Advanced Renal Cell Carcinoma Disease Background and Overview
6. Advanced Renal Cell Carcinoma Patient Journey
7. Advanced Renal Cell Carcinoma Epidemiology and Patient Population
8. Advanced Renal Cell Carcinoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Advanced Renal Cell Carcinoma Unmet Needs
10. Key Endpoints of Advanced Renal Cell Carcinoma Treatment
11. Advanced Renal Cell Carcinoma Marketed Products
12. Advanced Renal Cell Carcinoma Emerging Therapies
13. Advanced Renal Cell Carcinoma Seven Major Market Analysis
14. Attribute Analysis
15. Advanced Renal Cell Carcinoma Market Outlook (7 major markets)
16. Advanced Renal Cell Carcinoma Access and Reimbursement Overview
17. KOL Views on the Advanced Renal Cell Carcinoma Market.
18. Advanced Renal Cell Carcinoma Market Drivers
19. Advanced Renal Cell Carcinoma Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Related Reports
Advanced Renal Cell Carcinoma (RCC) Epidemiology Forecast to 2030
DelveInsight’s ‘Advanced Renal Cell Carcinoma (RCC) Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Advanced Renal Cell Carcinoma (RCC) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Advanced Renal Cell Carcinoma (RCC) Pipeline Insights, 2020
Advanced Renal Cell Carcinoma (RCC) Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Advanced Renal Cell Carcinoma (RCC) market.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/